Compare Stocks: BCAX, ERAS, DNTH, and EWTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$17.63	$23.57	$13.70 ▼ $30.99	$1.17B	-0.7	670,217 shs	763,073 shs
DNTH Dianthus Therapeutics	$88.21	$104.79	$32.22 ▼ $117.88	$4.83B	1.35	890,098 shs	751,384 shs
ERAS Erasca	$14.74	$16.85	$2.11 ▼ $24.28	$5.16B	0.61	4.56 million shs	3.84 million shs
EWTX Edgewise Therapeutics	$41.40	$42.92	$14.25 ▼ $48.51	$4.50B	0.35	1.67 million shs	1.43 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	0.00%	-8.22%	-23.91%	-39.66%	+3.46%
DNTH Dianthus Therapeutics	0.00%	-0.38%	-18.40%	-5.50%	+152.46%
ERAS Erasca	0.00%	+3.44%	-8.96%	-21.80%	+509.09%
EWTX Edgewise Therapeutics	0.00%	+5.24%	-3.88%	+3.24%	+164.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$17.63	$23.57	$13.70 ▼ $30.99	$1.17B	-0.7	670,217 shs	763,073 shs
DNTH Dianthus Therapeutics	$88.21	$104.79	$32.22 ▼ $117.88	$4.83B	1.35	890,098 shs	751,384 shs
ERAS Erasca	$14.74	$16.85	$2.11 ▼ $24.28	$5.16B	0.61	4.56 million shs	3.84 million shs
EWTX Edgewise Therapeutics	$41.40	$42.92	$14.25 ▼ $48.51	$4.50B	0.35	1.67 million shs	1.43 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	0.00%	-8.22%	-23.91%	-39.66%	+3.46%
DNTH Dianthus Therapeutics	0.00%	-0.38%	-18.40%	-5.50%	+152.46%
ERAS Erasca	0.00%	+3.44%	-8.96%	-21.80%	+509.09%
EWTX Edgewise Therapeutics	0.00%	+5.24%	-3.88%	+3.24%	+164.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	2.75	Moderate Buy	$32.64	85.12% Upside
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$129.83	47.19% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	49.87% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$51.33	23.99% Upside

Current Analyst Ratings Breakdown

Latest BCAX, ERAS, DNTH, and EWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	BCAX Bicara Therapeutics	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Equal Weight
9/21/2026	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $57.00
9/11/2026	DNTH Dianthus Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$135.00
9/10/2026	BCAX Bicara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/8/2026	ERAS Erasca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/4/2026	DNTH Dianthus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$156.00
8/21/2026	BCAX Bicara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $60.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	ERAS Erasca	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.33 per share	N/A
DNTH Dianthus Therapeutics	$2.04M	2,369.56	N/A	N/A	$11.41 per share	7.73
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)

Latest BCAX, ERAS, DNTH, and EWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	11.59	11.59
DNTH Dianthus Therapeutics	N/A	26.10	26.10
ERAS Erasca	N/A	8.29	8.29
EWTX Edgewise Therapeutics	N/A	16.24	16.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
DNTH Dianthus Therapeutics	47.53%
ERAS Erasca	67.78%
EWTX Edgewise Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	13.80%
DNTH Dianthus Therapeutics	3.02%
ERAS Erasca	14.20%
EWTX Edgewise Therapeutics	21.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	103	66.17 million	57.04 million	N/A
DNTH Dianthus Therapeutics	92	54.80 million	53.14 million	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable

BCAX, ERAS, DNTH, and EWTX Headlines

Recent News About These Companies

Wall Street Zen Upgrades Edgewise Therapeutics (NASDAQ:EWTX) to Hold

October 4 at 1:11 AM | marketbeat.com

Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?

October 2 at 11:53 PM | finance.yahoo.com

Edgewise Therapeutics (NASDAQ:EWTX) Shares Climb 5.9% - Still a Buy?

October 2 at 7:21 AM | americanbankingnews.com

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

October 1, 2026 | prnewswire.com

Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 5.9% - What's Next?

September 30, 2026 | marketbeat.com

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock Has Consensus Target Price of $51.33

September 28, 2026 | americanbankingnews.com

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Rating of "Moderate Buy" from Analysts

September 28, 2026 | marketbeat.com

Edgewise Therapeutics (NASDAQ:EWTX) Rating Lowered to Sell at Wall Street Zen

September 26, 2026 | americanbankingnews.com

Wall Street Zen Downgrades Edgewise Therapeutics (NASDAQ:EWTX) to Sell

September 26, 2026 | marketbeat.com

Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says

September 25, 2026 | finance.yahoo.com

Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says

September 23, 2026 | finance.yahoo.com

Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 7.2% - Should You Sell?

September 23, 2026 | marketbeat.com

Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript

September 22, 2026 | seekingalpha.com

Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow

September 22, 2026 | seekingalpha.com

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

September 22, 2026 | prnewswire.com

Edgewise Therapeutics (NASDAQ:EWTX) Price Target Raised to $57.00 at HC Wainwright

September 21, 2026 | marketbeat.com

Bank of America Corp DE Takes Position in Edgewise Therapeutics, Inc. $EWTX

September 20, 2026 | marketbeat.com

Biotech Options Buzz: UTHR, NMRA, EWTX

September 18, 2026 | schaeffersresearch.com

Investors Buy High Volume of Call Options on Edgewise Therapeutics (NASDAQ:EWTX)

September 18, 2026 | marketbeat.com

Edgewise Therapeutics (NASDAQ:EWTX) Hits New 52-Week High - Here's Why

September 17, 2026 | marketbeat.com

91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC

September 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, ERAS, DNTH, and EWTX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$17.63 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$17.62 0.00 (-0.03%)

As of 10/2/2026 07:30 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Dianthus Therapeutics NASDAQ:DNTH

$88.21 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$88.30 +0.09 (+0.10%)

As of 10/2/2026 07:30 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Erasca NASDAQ:ERAS

$14.74 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$14.72 -0.02 (-0.14%)

As of 10/2/2026 07:36 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Edgewise Therapeutics NASDAQ:EWTX

$41.40 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$41.40 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCAX, ERAS, DNTH, and EWTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCAX, ERAS, DNTH, and EWTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCAX, ERAS, DNTH, and EWTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, ERAS, DNTH, and EWTX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Dianthus Therapeutics NASDAQ:DNTH

Erasca NASDAQ:ERAS

Edgewise Therapeutics NASDAQ:EWTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCAX, ERAS, DNTH, and EWTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCAX, ERAS, DNTH, and EWTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCAX, ERAS, DNTH, and EWTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, ERAS, DNTH, and EWTX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Dianthus Therapeutics NASDAQ:DNTH

Erasca NASDAQ:ERAS

Edgewise Therapeutics NASDAQ:EWTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools